EPIGENETIC EFFECTS OF ENZASTAURIN – A NEW ASPECT IN THE MECHANISM OF ACTION OF AN ANTICANCER DRUG FROM PROTEIN KINASE INHIBITORS

The purpose of the study was to analyze the ability of five antitumor drugs from the pharmaceutical group of protein kinase inhibitors (gefitinib, imatinib, pazopanib, ponatinib and enzastaurin) to reactivate the expression of the epigenetically silenced GFP in HeLa TI cells, and to estimate the eff...

全面介紹

書目詳細資料

Principais autores:	V. P. Maksimova, J. V. Makus, O. G. Usalka, E. S. Lylova, P. E. Bugaeva, E. M. Zhidkova, D. A. Fedorov, O. P. Lizogub, E. A. Lesovaya, G. A. Belitsky, M. G. Yakubovskaya, K. I. Kirsanov
格式:	Artigo
語言:	Russo
出版:	Russian Academy of Sciences, Tomsk National Research Medical Center 2020-09-01
叢編:	Сибирский онкологический журнал
主題:	protein kinase inhibitors enzastaurin epigenetic activity hela ti histone modifications dna methylation hat hdac
在線閱讀:	https://www.siboncoj.ru/jour/article/view/1531
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!